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CRT-162
Impella® and Tandem Heart® for Circulatory Support in Refractory Cardiogenic Shock
Guillermo Andres Cortes, Kevin Platt, Ryan Kobayashi, Ray Matthews,
Anilkumar Mehra, Michael Gaglia, David Shavelle, Leonardo Clavijo
University of Southern California, Los Angeles, CA
Background: Previous studies demonstrate that in patients with cardiogenic shock the
Impella® (Abiomed, Danvers, MA) and Tandem Heart® (CardiacAssist, Pittsburg,
PA) percutaneous left ventricular hemodynamic support devices improve cardiac index,
systemic blood pressure and mixed venous oxygen saturation. These devices are
expensive, survival data in this patient population is missing and comparisons between
devices are lacking.
Study Objective: Compare clinical and procedural characteristics, outcomes and
complications in patients with refractory cardiogenic shock (RCS) treated with the TH
and IMP for hemodynamic support.
Methods: Baseline demographics, clinical characteristics, procedural information and
hospital outcomes were investigated from January 2008 to June 2013 in patients
treated with either IMP or TH at Keck Medical Center of USC and LAC-USC
Medical Center.
Results: A total of 83 patients had TH or IMP for circulatory support; 20 patients
had device implantation for RCS (12 TH and 8 IMP). Mean age was 54.116.4,
80% of patients were male, 45% smokers, 35% diabetic and 20% CRI. Ischemic
cardiomyopathy was the etiology of RCS in 55% of patients. Ejection fraction
averaged 2112%. IMP patients were older (669 vs. 4615, p¼0.004). The
overall mortality was 65% (TH 58.3% vs. IMP 75%, p¼0.64). Table outlines
in-hospital outcomes.
Conclusions: In this small patient cohort we found no signiﬁcant difference between
IMP and TH for the treatment of RCS. Vascular, neurological and rhythm related
complications were similar. Overall mortality remains high in patients with RCS
despite TH and IMP support. Prospective trials and comparative studies of TH and
IMP in patients with RCS are needed before a recommendation for use is made.In-hospital outcomesComplications All n (%) Impella® n (%)
Tandem
Heart® n (%) p valueArrhythmia 8 (40.0) 3(37.50) 5(41.67) 1.0Vascular Repair 1(5.0) 0(0) 1(8.33) 1.0Acute Limb Ischemia 2(10.0) 1(12.50) 1(8.33) 1.0Hematoma 1(5.0) 0(0) 1(8.33) 1.0Acute Renal Failure 16(80.0) 7(87.50) 9(75.0) 0.62GI Bleed 1(5.0) 0(0) 1(8.33) 1.0Stroke 2(10.0) 1(12.50) 1(8.33) 1.0Death 13(65.0) 6(75.0) 7(58.33) 0.64ENDOVASCULAR-Renal Intervention
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Long Term Safety and Efficacy of a Multi-electrode Renal Artery Denervation Catheter
in Patients with Drug-Resistant Hypertension: Twelve and 18 Month Results of a
First-in-Human, Multicenter Study
Vasilios Papademetriou,1 Costas Tsiouﬁs,1 Stephen Worthley2
1Georgetown University, Potomac, MD; 2Monash, Adelaide, Austria
Background: Recent estimates indicate that 8-12% of patients with hypertension do
not respond adequately to optimal medical therapy. Sympathetic renal artery
denervation is emerging as a viable treatment option for patients with drug resistant
HTN but long-term results using multi-electrode ablations systems have not been
reported.
Methods and Results: The EnligHTN renal denervation system (St Jude Medical)
has 4 electrodes attached on a basket mounted at the tip of the catheter and can deliver
multiple transmural lesions in a predetermined pattern. The EnligHTN-I ﬁrst-
in-human study was designed to assess the safety and efﬁcacy of this multi-electrode
ablation system in patients with drug-resistant hypertension. A total of 46 pts (av. age
6010yrs, on 4.80.6 meds) were enrolled. Of these pts 33% were female, 98% were
white, 20% had Coronary Artery Disease, 59% had hyperlipidemia, 33% had type II
Diabetes Mellitus, and 30% had history of sleep apnea. On average 7.70.8 lesions
were created in the right renal artery and 7.41.4 in the left. Baseline av. ofﬁce BP was
176/96 mmHg and average 24 hr ambulatory BP 150/83 mmHg. Average reductions
(mmHg) of ofﬁce BP at 1, 3, 6 and 12 months were -28/10, -27/10, -26/10 and -27/
11 mmHg (p<0.001) respectively and for 24hr ambulatory BP -10/5, -10/5 and -10/
6 mmHg (p<0.001) data for 12 month N/A. At 12 months 80% of patients were
responders, 75% had ofﬁce BP <160 systolic and 29% had normalized BP. At
6 months there was a small reduction in the estimated glomerular ﬁltration rate (from
87 to 82 mL/min/1.73m2) driven by a small increase in serum creatinine from 78 to
83 mmol/L), but both values returned to baseline at 12 months. Cystatin C levels and
microalbuminuria improved signiﬁcantly up to 12 months. There were 3 device/pro-
cedure related serious adverse events reported to date: hypertensive renal disease
progression, symptomatic hypotension and worsening of pre-existing renal artery
stenosis. Eighteen month efﬁcacy and safety data will be available to be presented at
the meeting.
Conclusions: We conclude that data demonstrates that the EnligHTN ablation
system continues to be safe and effective in the treatment of patients with drug-
resistant hypertension.TECHNOLOGY-Renal Denervation
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Renal Denervation Using Standard 5F Radiofrequency Ablation Catheter in Patients
with End Stage Renal Disease: A 6 Month Follow-Up
Amitabh Yaduvanshi, Sanjib Patra, Sanjeev Gupta, Mohan Nair
Saket City Hospital, New Delhi, India
Background: Renal denervation has been proven to be beneﬁcial in treating resistant
hypertension in patients with normal renal function. There are a signiﬁcant number of
